Spread The News
Forward to a Friend
Print This Story
Write a Comment
More Industry Headlines
Biomeds urged to 'think beyond the basement' Speakers at AAMI/ECRI Institute meeting offer ways biomeds can get more recognition from the C-suite.
Subscribers only: PACS vendor tries new business model With hospitals' capital budgets depleted by EMR purchases, Merge Healthcare looks to subscriptions.
Medical device tax repeal amendment added to Senate FDA user fee bill Amendment would kill excise tax.
Say no to PSA screenings, USPSTF says Prostate cancer tests do more harm than good, panel says.
Medical groups recommend annual lung CT scans for heavy smokers Should heavy smokers get annual CT lung screenings?
Weird news: Stolen medical equipment contaminated with brain disease Equipment used on Creutzfeldt-Jakob disease patient.
FCC could open spectrum to wireless body sensors FCC to rule on MBANs next week.
VNAs on the rise: forecast Plus, PACS will store a heck of a lot of images by 2016.
World ultrasound sales to grow 29 percent over next 5 years Asia Pacific region to drive sector's growth.
Agfa opens Canadian PACS, RIS R&D center Center opens in Waterloo, Ontario.
FDA rejects imaging agent for Alzheimer's disease detection
Amyvid, a PET imaging agent under investigation for the detection of beta-amyloid plaque in living patients' brains, is produced by Eli Lilly and Company's subsidiary Avid Radiopharmaceuticals, Inc.
NEW! Wireless Foot & Hand Switch for GE-OEC Mobile C-Arms
In its denial of approval for the dye, the FDA focused "on the need to establish a reader training program for market implementation that helps to ensure reader accuracy and consistency of interpretations of existing Amyvid scans," the drug's makers said in a statement.
In January, an FDA advisory panel asked the company for more evidence on the florbetapir F18 agent. The companies said they've been working on the issues raised by the panel and are continuing to cooperate with the FDA.
"Lilly and Avid have been engaged in an active and ongoing dialogue with the FDA," said Wei-Li Shao, Lilly brand director for the agent. "We remain confident in the data submission package for Amyvid."
Interested in Medical Industry News?
Subscribe to DOTmed's weekly news email and always be informed.
Click here, it takes just 30 seconds.
You Must Be Logged In To Post A Comment
|
||||||||
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2012 DOTmed.com, Inc.
ALL RIGHTS RESERVED
